P3 Health Partners (NASDAQ:PIII – Get Free Report) and Precipio (NASDAQ:PRPO – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation and institutional ownership.
Analyst Recommendations
This is a breakdown of recent recommendations for P3 Health Partners and Precipio, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| P3 Health Partners | 1 | 2 | 1 | 0 | 2.00 |
| Precipio | 1 | 0 | 0 | 0 | 1.00 |
P3 Health Partners currently has a consensus price target of $3.50, suggesting a potential upside of 39.78%. Given P3 Health Partners’ stronger consensus rating and higher possible upside, equities research analysts clearly believe P3 Health Partners is more favorable than Precipio.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| P3 Health Partners | $1.46 billion | 0.01 | -$147.95 million | ($45.20) | -0.06 |
| Precipio | $24.05 million | 2.13 | -$360,000.00 | ($0.25) | -114.72 |
Precipio has lower revenue, but higher earnings than P3 Health Partners. Precipio is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
7.8% of P3 Health Partners shares are owned by institutional investors. Comparatively, 10.4% of Precipio shares are owned by institutional investors. 17.8% of P3 Health Partners shares are owned by company insiders. Comparatively, 16.9% of Precipio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Volatility and Risk
P3 Health Partners has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500. Comparatively, Precipio has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500.
Profitability
This table compares P3 Health Partners and Precipio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| P3 Health Partners | -10.14% | -302.33% | -20.72% |
| Precipio | -1.51% | -2.78% | -1.84% |
Summary
Precipio beats P3 Health Partners on 8 of the 14 factors compared between the two stocks.
About P3 Health Partners
P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. P3 Health Partners Inc. was founded in 2020 and is based in Henderson, Nevada.
About Precipio
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.
Receive News & Ratings for P3 Health Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for P3 Health Partners and related companies with MarketBeat.com's FREE daily email newsletter.
